Mario Gabelli Paratek Pharmaceuticals, Inc. Transaction History

Gamco Investors, Inc. Et Al

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$1.52 - $2.8 $5,168 - $9,520	3,400 Added 21.94%	18,900 $41,000
Q4 2022 Feb 13, 2023	SELL	$1.67 - $2.51 $56,780 - $85,340	-34,000 Reduced 68.69%	15,500 $28,000
Q1 2022 May 13, 2022	BUY	$2.94 - $4.77 $1,470 - $2,385	500 Added 1.02%	49,500 $147,000
Q4 2021 Feb 11, 2022	BUY	$4.07 - $5.3 $61,050 - $79,500	15,000 Added 44.12%	49,000 $220,000
Q3 2021 Nov 12, 2021	BUY	$4.7 - $7.24 $159,800 - $246,160	34,000 New	34,000 $165,000
Q2 2021 Aug 13, 2021	SELL	$6.81 - $10.93 $88,530 - $142,090	-13,000 Closed	0 $0
Q4 2020 Feb 05, 2021	SELL	$4.58 - $7.14 $5,496 - $8,568	-1,200 Reduced 8.45%	13,000 $81,000
Q3 2020 Nov 06, 2020	SELL	$4.19 - $6.69 $146,650 - $234,150	-35,000 Reduced 71.14%	14,200 $77,000
Q2 2020 Aug 13, 2020	SELL	$2.97 - $5.22 $19,305 - $33,930	-6,500 Reduced 11.67%	49,200 $257,000
Q2 2019 Aug 02, 2019	SELL	$3.47 - $6.32 $7,981 - $14,536	-2,300 Reduced 3.97%	55,700 $222,000
Q1 2019 May 02, 2019	SELL	$5.36 - $7.24 $5,360 - $7,240	-1,000 Reduced 1.69%	58,000 $311,000
Q4 2018 Jan 30, 2019	BUY	$4.8 - $11.6 $283,200 - $684,400	59,000 New	59,000 $303,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.